Selective estrogen receptor modulators and aromatase inhibitors for breast cancer chemoprevention

Current Drug Targets

Volumn 12, Issue 13, 2011, Pages 1874-1887

  Vogel, Victor G ^a  

^a GEISINGER HEALTH SYSTEM   (United States)

Author keywords

Aromatase inhibitors; Raloxifene; Risk reduction selective estrogen receptor modulators; Tamoxifen

Indexed keywords

ANASTROZOLE; ANDROGEN; AROMATASE INHIBITOR; ESTROGEN; ESTROGEN RECEPTOR; EXEMESTANE; LASOFOXIFENE; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ARTHRITIS; ARTICLE; BENIGN UTERUS TUMOR; BREAST CANCER; CANCER INCIDENCE; CANCER INVASION; CANCER MORTALITY; CANCER RISK; CARDIOTOXICITY; CATARACT; CHEMOPROPHYLAXIS; CHOLELITHIASIS; DEEP VEIN THROMBOSIS; DEPRESSION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG SAFETY; DYSPAREUNIA; DYSPEPSIA; ENDOMETRIUM CANCER; FLU LIKE SYNDROME; FRACTURE; GYNECOLOGIC DISEASE; HEART MUSCLE ISCHEMIA; HOT FLUSH; HUMAN; INTERMITTENT CLAUDICATION; LEG CRAMP; LUNG EMBOLISM; MUSCLE SPASM; MUSCULOSKELETAL DISEASE; PERIPHERAL EDEMA; POSTMENOPAUSE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SIDE EFFECT; STROKE; THROMBOEMBOLISM; TREATMENT OUTCOME; URINE INCONTINENCE; UROGENITAL TRACT DISEASE; VAGINA DISCHARGE; VAGINAL DRYNESS; VASOMOTOR DISORDER; VERTEBRA FRACTURE; WEIGHT GAIN;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOPREVENTION; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; ITALY; MASS SCREENING; RALOXIFENE; RISK ASSESSMENT; RISK REDUCTION BEHAVIOR; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 82055161851     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945011798184164     Document Type: Article

References (55)

1. Wattenberg LW. Chemoprevention of cancer. Cancer Res 1985; 45: 1-8.
2. Lippman SM, Benner SE, Hong WK. Cancer chemoprevention. J Clin Oncol 1994; 12: 851-73.
3. O'Shaughnessy JA. Chemoprevention of breast cancer. JAMA 1996; 275: 1349-53.
4. Sporn MB, Suh N. Chemoprevention of cancer. Carcinogenesis 2000; 21: 525-30.
5. Sporn MB, Suh N. Chemoprevention: an essential approach to controlling cancer. Nature Reviews. Cancer 2002; 2: 537-43.
6. Vogel VG. Chemoprevention: reducing breast cancer risk. In Vogel VG (ed): Management of patients at high risk for breast cancer, Malden, MA, Blackwell Science, 2001.
7. Bernstein L. Epidemiology of endocrine-related risk factors for breast cancer. J Mammary Gland Biology & Neoplasia 2002; 7: 3-15.
8. Kelsey JL, Gammon MD, John EM. Reproductive factors and breast cancer. Epidemiol Rev 1993; 15: 36-47.
9. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989; 81: 1879-86.
10. The tool can be accessed at www.cancer.gov/bcrisktool
11. Freedman AN, Graubard BI, Rao SR, et al. Estimates of the number of U.S. women who could benefit from tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst 2003; 95: 526-32.
12. Russo J, Russo IH. Toward a physiological approach to breast cancer prevention. Cancer Epidemiol Biomarkers Prev 1994; 3: 354-64.
13. Henderson BE, Ross RK, Pike MC. Hormonal chemoprevention of cancer in women. Science 1993; 259: 633-8.
14. Petrakis NL, Ernster VL, King MC. Breast. In Schottenfeld D, Fraumeni JF Jr (eds): Cancer epidemiology and prevention, Philadelphia, 1982, WB Saunders.
15. Jordan VC. Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata. Eur J Cancer 1976; 12: 419-24.
16. Jordan VC. Antiestrogenic and antitumor properties of tamoxifen in laboratory animals. Cancer Treatment Reports 1976; 60: 1409-19.
17. Jordan VC, Murphy CS. Endocrine pharmacology of antiestrogens as antitumor agents. Endocr Rev 1990; 11: 578-610.
18. Jordan VC. Chemosuppression of breast cancer with long-term tamoxifen therapy. Prev Med 1991; 20: 3-14.
19. Goetz MP, Rae JM, Suman VJ, et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005; 23: 9312-8.
20. Vogel VG. Raloxifene: a second-generation selective estrogen receptor modulator for reducing the risk of invasive breast cancer in postmenopausal women. Women's Health 2007; 3: 139-53.
21. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90: 1371-88.
22. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 2005; 97: 1652-62.
23. Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomized chemoprevention trial. Lancet 1998; 352: 98-101.
24. Powles TJ. The Royal Marsden Hospital (RMH) trial: key points and remaining questions. Ann NY Acad Sci 2001; 949: 109.
25. Powles TJ. Twenty-Year Follow-up of the Royal Marsden Randomized, Double-Blinded Tamoxifen Breast Cancer Prevention Trial. J Natl Cancer Inst 2007; 99: 283-90.
26. Veronesi U, Maisonneuve P, Sacchini V, et al. Tamoxifen for breast cancer among hysterectomized women. Lancet 2002; 359: 1122-24.
27. Veronesi U, Mariani L, Decensi A, et al. Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. Ann Oncol 2006; 17: 1065-71.
28. Veronesi U, Maisonneuve P, Rotmensz N, et al. Tamoxifen for the Prevention of Breast Cancer: Late results of the Italian randomized tamoxifen prevention trial among women with hysterectomy, J Natl Cancer Inst 2007; 99: 727-37.
29. IBIS Investigators. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 2002; 360: 817-24.
30. Cuzick J, Forbes JF, Sestak I, et al. Long-term results of tamoxifen prophylaxis for breast cancer: 96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 2007; 99: 272-82.
31. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 2005; 97: 1652-62.
32. Love RR, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992; 326: 852.
33. Love RR, et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med 1991; 115: 860.
34. Day R, Ganz PA, Costantino JP, Cronin WM, Wickerham DL, Fisher B. Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Clin Oncol 1999; 17: 2659-69.
35. Day R, Ganz PA, Costantino JP. Tamoxifen and depression: more evidence from the National Surgical Adjuvant Breast and Bowel Project's Breast Cancer Prevention (P-1) randomized study. J Natl Cancer Inst 2001; 93: 1615-23.
36. Powles, TJ. Twenty-Year Follow-up of the Royal Marsden Randomized, Double-Blinded Tamoxifen Breast Cancer Prevention Trial, J Natl Cancer Inst 2007; 99: 283-90.
37. Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003; 361: 296-300.
38. Gail MH, Costantino JP, Bryant J, et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 1999; 91: 29.
39. McCaskill-Stevens W, Wilson J, Bryant J, et al. Contralateral breast cancer and thromboembolic events in African American women treated with tamoxifen. J Natl Cancer Inst 2004; 96: 1762-9.
40. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. JAMA 1999; 281: 2189-97.
41. Cauley JA, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4- year results from the MORE trial. Breast Cancer Res Treat 2001; 65: 125-34.
42. Martino S, Cauley JA, Barrett-Connor E, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004; 96: 1751-61.
43. Barrett-Connor E, Mosca L, Collins P, et al. Raloxifene Use for The Heart (RUTH) Trial Investigators. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006; 355: 125-37.
44. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial. JAMA 2006; 295: 2727-41.
45. Land SR, Wickerham DL, Costantino JP, et al. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial. JAMA 2006; 295: 2742-51.
46. Geller BA, Vogel VG. Chemoprevention of breast cancer in postmenopausal women. Breast Disease 2005-2006; 24: 79-92.
47. Zanardi S, Serrano D, Argusti A, et al. Clinical trials with retinoids for breast cancer chemoprevention. Endocrine-Related Cancer 2006; 13: 51-68.
48. Richardson HD, Johnston J, Pater P. Goss. The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial. Curr Oncol 2007; 14: 89-96.
49. Cuzick J. IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole. Expert Rev Anticancer Ther 2008; 9: 1377-85.
50. Vogel VG, Costantino JP, Wickerham DL, et al. Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowell Project breast cancer chemoprevention trials. J Natl Cancer Inst Monographs 2010; 2010: 181-6.
51. Port ER, Montgomery LL, Heerdt AS, Borgen PI. Patient reluctance toward tamoxifen use for breast cancer primary prevention. Ann Surg Oncol 2001; 8: 580-5.
52. Cummings SR, Ensrud K, Delmas PD, et al. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med 2010; 362: 686-96.
53. LaCroix AZ, Powles T, Osborne CK, et al. Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. J Natl Cancer Inst 2010; 102: 1706-15.
54. Vogel VG. Tipping the balance for the primary prevention of breast cancer. (Editorial). J Natl Cancer Inst 2010; 102: 1-3.
55. Goss PE, Ingle JN, Alés-Martínez JE, et al. Exemestane for breastcancer prevention in postmenopausal women. N Engl J Med 2011; 364: 2381-91.